ArticleScientific reports2024
Continuous glucose monitoring among adults with type 2 diabetes receiving noninsulin or basal insulin therapy in primary care.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Continuous glucose monitoring in noninsulin-treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials.Diabetes, obesity & metabolism · 2025Pooled it
- Beyond Coverage Expansion: Exploring Persistent Barriers to CGM Utilization in the Clinical Environment.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Digital phenotyping of CGM engagement reveals distinct glycemic outcomes.PLOS digital health · 2026Article
- Psychological Aspects and Implications of Food Addiction and Glucose Control in Type 2 Diabetes: A Pilot Mixed-Methods Study.Healthcare (Basel, Switzerland) · 2026Article
- The Expanding Role of Continuous Glucose Monitoring in the Management and Prevention of Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Impact of Real-Time Continuous Glucose Monitoring on Medication Use and Glycemic Control in Type 2 Diabetes Across Therapy Regimens.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Characterizing Continuous Glucose Monitoring Prescription Patterns Between 2020 and 2024: A Retrospective Study at a Single Primary Care Facility in the United States.Journal of diabetes research · 2026Article
- Postprandial glycemic response in different ethnic groups in East London and its association with vitamin D status: Study protocol for an acute randomized crossover trial.Nutrition and health · 2025Article
- LLM-Powered Prediction of Hyperglycemia and Discovery of Behavioral Treatment Pathways from Wearables and Diet.Sensors (Basel, Switzerland) · 2025Article
- Future horizons in diabetes: integrating AI and personalized care.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rates of type 2 diabetes (T2D) continue to rise in the United States, with many patients failing to achieve glycemic targets. Primary care providers often serve as the sole clinician managing diabetes. Continuous glucose monitors (CGMs) have shown promise in diabetes management, yet their adoption in primary care settings, especially among patients with T2D not using intensive insulin therapy, remains limited. We sought to evaluate the impact of CGM use on glycemic control in patients with T2D not using insulin and those using basal but not bolus insulin in a primary care setting. CGM use was associated with a significantly greater reduction in HbA1c (-0.62%, p < 0.01) compared with matched controls at 3 months (n = 182). Patients showed improvements in time in range (39.7-61.9%, p < 0.0001), time > 180 mg/dL (60.1-37.9%, p < 0.001), time > 250 mg/dL (27.6-8.5%, p < 0.001), mean estimated glucose value (212 mg/dL to 173 mg/dL, p < 0.001) and glucose management indicator (8.39-7.46%, p < 0.001). CGM use in a primary care setting compared to usual care significantly improved glycemic control in T2D patients not on bolus insulin, irrespective of treatment with non-insulin or basal insulin. This suggests potential for broader CGM integration in primary care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.